Table 2.
Association between pre-treatment FIB-4 score and HCC risk among patients with or without baseline cirrhosis who achieved SVR, stratified by type of antiviral treatment.
| Number of patients (%) | Patient-years | Number who developed HCC (%) | HCC per 100 patient-years | Crude hazard ratio (95% CI) | Adjusted* hazard ratio (95%CI) | ||
|---|---|---|---|---|---|---|---|
| CIRRHOSIS | |||||||
| IFN-based REGIMENS | FIB-4 <3.25 | 1,208(53.7) | 9,286 | 63(5.2) | 0.68 | 1 | 1 |
| FIB-4 ≥3.25 | 1,043(46.3) | 6,283 | 168(16.1) | 2.67 | 3.91 (2.93–5.23) | 2.78 (1.91–4.03) | |
| DAA-only REGIMENS | FIB-4 <3.25 | 2,546(33.8) | 7,753 | 90(3.5) | 1.16 | 1 | 1 |
| FIB-4 ≥3.25 | 4,987(66.2) | 14,448 | 529(10.6) | 3.66 | 3.17 (2.54–3.96) | 2.14 (1.66–2.75) | |
| NO CIRRHOSIS | |||||||
| IFN-based REGIMENS | FIB-4 <3.25 | 14,921(88.5) | 143,790 | 203(1.4) | 0.14 | 1 | 1 |
| FIB-4 ≥3.25 | 1,930(11.5) | 15,663 | 168(8.7) | 1.07 | 7.79 (6.34–9.56) | 5.11 (3.94–6.62) | |
| DAA-only REGIMENS | FIB-4 <3.25 | 16,818(78.2) | 50,029 | 121(0.7) | 0.24 | 1 | 1 |
| FIB-4 ≥3.25 | 4,682(21.8) | 13,651 | 167(3.6) | 1.22 | 5.06 (4.01–6.40) | 3.56 (2.74–4.63) | |
*
Adjusted for sex, race/ethnicity, body mass index, HCV genotype, HCV viral load, HIV co-infection, HBV co-infection, type 2 diabetes mellitus, alcohol use disorders, AUDIT-C score, substance use disorder, cirrhosis complications, serum bilirubin, serum creatinine, serum albumin, blood INR and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.